Antibodies to IL-6 and use thereof

US9879074B2 · kind B2 · utility

Assignee

• ALDERBIO HOLDINGS LLC · US

Inventors

• Leon F. Garcia-Martinez · Woodinville, US
• Anne Elisabeth Carvalho Jensen · Mill Creek, US
• Katie Olson Anderson · Kirkland, US
• Benjamin H. Dutzar · Seattle, US
• Ethan W. Ojala · Snohomish, US
• Brian R. Kovacevich · Snohomish, US
• John Latham · Seattle, US
• Jeffrey T. L. Smith · Dublin, IE

Key dates

• Filing date: May 29, 2015
• Grant date: Jan 30, 2018
• Expiry date: May 29, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.